$150,000 of NATERA INC lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Advocacy on importance of FDA's oversight of Laboratory Developed Tests and impact on industry and patients. Advocacy on CMS administrative procedures regarding Date of Service (DOS) for Laboratory testing for patients."
You can find more data on corporate lobbying on Quiver Quantitative.
NTRA Congressional Stock Trading
Members of Congress have traded $NTRA stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/22 and 1 sale worth up to $15,000 on 07/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
NTRA Insider Trading Activity
NTRA insiders have traded $NTRA stock on the open market 181 times in the past 6 months. Of those trades, 0 have been purchases and 181 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 14 sales selling 112,436 shares for an estimated $18,755,165.
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 26 sales selling 68,093 shares for an estimated $10,508,184.
- JONATHAN SHEENA has made 0 purchases and 59 sales selling 39,447 shares for an estimated $6,546,210.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 9 sales selling 26,193 shares for an estimated $4,330,531.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 29 sales selling 25,523 shares for an estimated $3,922,784.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 22 sales selling 18,161 shares for an estimated $2,679,046.
- GAIL BOXER MARCUS has made 0 purchases and 13 sales selling 14,795 shares for an estimated $2,316,079.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 8 sales selling 6,217 shares for an estimated $927,245.
- ROWAN E CHAPMAN sold 2,750 shares for an estimated $459,222
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NTRA Hedge Fund Activity
We have seen 368 institutional investors add shares of NTRA stock to their portfolio, and 262 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 3,263,822 shares (+44.3%) to their portfolio in Q2 2025, for an estimated $551,390,088
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,650,073 shares (+15.7%) to their portfolio in Q2 2025, for an estimated $278,763,332
- CITADEL ADVISORS LLC removed 1,301,513 shares (-61.3%) from their portfolio in Q2 2025, for an estimated $219,877,606
- KYNAM CAPITAL MANAGEMENT, LP removed 1,167,570 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $197,249,275
- CAPITAL WORLD INVESTORS added 1,013,229 shares (+255.6%) to their portfolio in Q2 2025, for an estimated $171,174,907
- LORD, ABBETT & CO. LLC removed 736,644 shares (-48.4%) from their portfolio in Q2 2025, for an estimated $124,448,637
- POINTSTATE CAPITAL LP removed 615,287 shares (-81.4%) from their portfolio in Q2 2025, for an estimated $103,946,585
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NTRA Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 10/14/2025
- Stephens & Co. issued a "Overweight" rating on 08/15/2025
- Piper Sandler issued a "Overweight" rating on 08/11/2025
- Barclays issued a "Overweight" rating on 08/08/2025
- RBC Capital issued a "Outperform" rating on 08/08/2025
- Evercore ISI Group issued a "Outperform" rating on 07/28/2025
- UBS issued a "Buy" rating on 05/09/2025
To track analyst ratings and price targets for NTRA, check out Quiver Quantitative's $NTRA forecast page.
NTRA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 8 analysts offer price targets for $NTRA in the last 6 months, with a median target of $205.0.
Here are some recent targets:
- Kyle Mikson from Canaccord Genuity set a target price of $200.0 on 10/14/2025
- Brandon Couillard from Wells Fargo set a target price of $175.0 on 09/22/2025
- Mason Carrico from Stephens & Co. set a target price of $183.0 on 08/15/2025
- David Westenberg from Piper Sandler set a target price of $220.0 on 08/11/2025
- Luke Sergott from Barclays set a target price of $210.0 on 08/08/2025
- Conor McNamara from RBC Capital set a target price of $255.0 on 08/08/2025
- Daniel Markowitz from Evercore ISI Group set a target price of $170.0 on 07/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
